N@N

Kostas Biliouris Maintained (SRPT) at Buy and Held Target at $170 on, Jun 18th, 2024

Kostas Biliouris of BMO Capital, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Buy and Held Target at $170 on, Jun 18th, 2024.

Kostas has made no other calls on SRPT in the last 4 months.

There are 12 other peers that have a rating on SRPT. Out of the 12 peers that are also analyzing SRPT, 3 agree with Kostas's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Brian Abrahams of "RBC Capital" Downgraded from Buy to Hold and Decreased Target to $142 on, Tuesday, May 28th, 2024
• Kristen Kluska of "Cantor Fitzgerald" Reiterated at Hold and Held Target at $128 on, Thursday, May 2nd, 2024
• Gavin Clark-Gartner of "Evercore ISI Group" Maintained at Hold with Increased Target to $138 on, Tuesday, February 20th, 2024

These are the ratings of the 9 analyists that currently disagree with Kostas

---

• Biren Amin of "Piper Sandler" Initiated at Buy and Held Target at $157 on, Friday, May 31st, 2024
• Gil Blum of "Needham" Reiterated at Strong Buy and Held Target at $166 on, Monday, May 20th, 2024
• Uy Ear of "Mizuho" Maintained at Strong Buy with Increased Target to $179 on, Friday, May 17th, 2024
• Hartaj Singh of "Oppenheimer" Upgraded from Hold to Buy and Held Target at $180 on, Tuesday, May 14th, 2024
• Anupam Rama of "JP Morgan" Maintained at Buy with Decreased Target to $175 on, Friday, May 3rd, 2024
• Colin Bristow of "UBS" Maintained at Strong Buy with Increased Target to $167 on, Friday, March 1st, 2024
• David Hoang of "Citigroup" Maintained at Strong Buy with Increased Target to $172 on, Thursday, February 29th, 2024
• Gena Wang of "Barclays" Maintained at Buy with Increased Target to $185 on, Thursday, February 29th, 2024
• Andreas Argyrides of "Wedbush" Reiterated at Buy and Held Target at $224 on, Tuesday, February 20th, 2024

Contributing Sources

---